See more : AdUX SA (ADUX.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Elevai Labs, Inc. Common Stock (ELAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Elevai Labs, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- GetFugu, Inc. (GFGU) Income Statement Analysis – Financial Results
- Jiangsu Daybright Intelligent Electric Co.,LTD. (300670.SZ) Income Statement Analysis – Financial Results
- Rockwool A/S (ROCK-A.CO) Income Statement Analysis – Financial Results
- Generation Bio Co. (GBIO) Income Statement Analysis – Financial Results
- Fine Organic Industries Limited (FINEORG.BO) Income Statement Analysis – Financial Results
Elevai Labs, Inc. Common Stock (ELAB)
Industry: Biotechnology
Sector: Healthcare
About Elevai Labs, Inc. Common Stock
Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 1.71M | 766.28K | 827.00 | 0.00 |
| Cost of Revenue | 578.02K | 324.00K | 2.85K | 0.00 |
| Gross Profit | 1.13M | 442.28K | -2.02K | 0.00 |
| Gross Profit Ratio | 66.25% | 57.72% | -244.01% | 0.00% |
| Research & Development | 426.24K | 228.75K | 123.63K | 118.86K |
| General & Administrative | 3.37M | 1.54M | 602.73K | 95.94K |
| Selling & Marketing | 660.29K | 192.86K | 31.61K | 6.08K |
| SG&A | 4.03M | 1.80M | 633.96K | 102.99K |
| Other Expenses | -3.32M | -198.44K | -25.45K | 0.00 |
| Operating Expenses | 1.13M | 2.23M | 783.04K | 222.91K |
| Cost & Expenses | 5.47M | 2.55M | 785.89K | 222.91K |
| Interest Income | 5.56K | 7.70K | 0.00 | 0.00 |
| Interest Expense | 19.53K | 2.63K | 0.00 | 0.00 |
| Depreciation & Amortization | 11.65K | 6.51K | 2.76K | 221.84K |
| EBITDA | -4.27M | -1.78M | -782.30K | -1.07K |
| EBITDA Ratio | -249.35% | -232.52% | -94,594.92% | 0.00% |
| Operating Income | -3.67M | -1.79M | -785.06K | -221.84K |
| Operating Income Ratio | -214.24% | -233.37% | -94,928.66% | 0.00% |
| Total Other Income/Expenses | -632.45K | -11.98K | 321.00 | -1.07K |
| Income Before Tax | -4.30M | -1.80M | -784.74K | -222.91K |
| Income Before Tax Ratio | -251.17% | -234.94% | -94,889.84% | 0.00% |
| Income Tax Expense | 0.00 | -2.00 | 3.00 | -1.07K |
| Net Income | -4.30M | -1.80M | -784.74K | -222.91K |
| Net Income Ratio | -251.17% | -234.94% | -94,889.84% | 0.00% |
| EPS | -0.40 | -0.19 | -0.05 | -0.05 |
| EPS Diluted | -0.40 | -0.19 | -0.05 | -0.05 |
| Weighted Avg Shares Out | 10.75M | 9.53M | 17.33M | 4.41M |
| Weighted Avg Shares Out (Dil) | 10.75M | 9.53M | 17.33M | 4.41M |
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
Taiwan is ELEVAI's third Asian contract for exosomes distribution after adding the Philippines in August of 2023 and Vietnam in May 2023 Asia-Pacific represents a combined $13 Billion prestige skincare and luxury haircare market 4, 5 Immediate access to 40...
Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results
Company reports record annual revenues of $1.71 Million for 2023, up 123.5% over the previous year Company reports record Q4 2023 revenues of $698,591, up 403% from Q4 2022 NEWPORT BEACH, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- Elevai Labs...
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical
Why Is Elevai Labs (ELAB) Stock Up 57% Today?
Elevai Labs (NASDAQ: ELAB ) stock is rocketing higher on Thursday as the skincare development company's shares experience heavy trading this morning. That has more than 9.4 million shares of ELAB stock changing hands of this writing.
ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
NEWPORT BEACH, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC.
ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach
ELEVAI Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach
Why Is Elevai Labs (ELAB) Stock Up Today?
Shares of medical aesthetics company Elevai Labs (NASDAQ: ELAB ) popped higher this morning following a key disclosure. Specifically, Elevai signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune Bio (NASDAQ: INMB ) to manufacture stem cells.
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
NEWPORT BEACH, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (Nasdaq: ELAB) a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce it has signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune...
ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences
NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC.
ELAB Stock Earnings: Elevai Labs Reported Results for Q3 2024
Elevai Labs (NASDAQ: ELAB ) just reported results for the third quarter of 2024. Elevai Labs reported earnings per share of -7.8 cents.
Source: https://incomestatements.info
Category: Stock Reports